Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

BACKGROUND: Patients with BRAF(V600E)-mutated metastatic colorectal cancer (mCRC) have a poorer prognosis as well as resistance to anti-EGFR antibodies. However, it is unclear whether BRAF mutations other than BRAF(V600E) (BRAF(non-V600E) mutations) contribute to anti-EGFR antibody resistance. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozaki, Eiji, Yoshino, Takayuki, Yamazaki, Kentaro, Muro, Kei, Yamaguchi, Kensei, Nishina, Tomohiro, Yuki, Satoshi, Shitara, Kohei, Bando, Hideaki, Mimaki, Sachiyo, Nakai, Chikako, Matsushima, Koutatsu, Suzuki, Yutaka, Akagi, Kiwamu, Yamanaka, Takeharu, Nomura, Shogo, Fujii, Satoshi, Esumi, Hiroyasu, Sugiyama, Masaya, Nishida, Nao, Mizokami, Masashi, Koh, Yasuhiro, Abe, Yukiko, Ohtsu, Atsushi, Tsuchihara, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680457/
https://www.ncbi.nlm.nih.gov/pubmed/28972961
http://dx.doi.org/10.1038/bjc.2017.308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680457/
https://www.ncbi.nlm.nih.gov/pubmed/28972961
http://dx.doi.org/10.1038/bjc.2017.308

Ejemplares similares